Overview Dividends

(CTXR) Citius Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US17322U2078

Immunotherapy, Antibiotic Solution, Topical Hemorrhoid

CTXR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -21.46%
EPS Trend (3Y Correlation): -76.3%

CTXR Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): 38.9%

Description: CTXR Citius Pharmaceuticals October 23, 2025

Citius Pharmaceuticals (NASDAQ:CTXR) is a U.S. biopharma focused on critical-care therapeutics. Its only FDA-approved product, LYMPHIR, treats cutaneous T-cell lymphoma, while its late-stage pipeline features Mino-Lok (an antibiotic lock solution for catheter-related bloodstream infections) and CITI-002 (Halo-Lido), a topical hemorrhoid therapy. Both the pivotal Phase 3 trial for Mino-Lok and the Phase 2b study for Halo-Lido have been completed, positioning the company for potential commercial launches pending regulatory clearance.

As of the most recent 10-Q (Q2 2024), Citius reported a cash runway of roughly $45 million, sufficient to fund its pipeline through at least 2026 assuming current burn rates (~$10 million per quarter). The biotech sector continues to benefit from strong venture capital inflows-U.S. biotech venture funding hit a record $27 billion in 2023-and an aging population that drives demand for infection-control and specialty dermatology products. However, the company’s market capitalization (~$150 million) reflects investor concern over execution risk and the need for successful product launches to generate sustainable revenue.

For a data-driven deep-dive into CTXR’s valuation metrics and comparable peers, consider reviewing the analytics available on ValueRay.

CTXR Stock Overview

Market Cap in USD	29m
Sub-Industry	Pharmaceuticals
IPO / Inception	2017-07-06

CTXR Stock Ratings

Growth Rating	-84.1%
Fundamental	30.1%
Dividend Rating	-
Return 12m vs S&P 500	-85.1%
Analyst Rating	4.0 of 5

CTXR Dividends

Currently no dividends paid

CTXR Growth Ratios

Growth Correlation 3m	40.9%
Growth Correlation 12m	-61.5%
Growth Correlation 5y	-88.9%
CAGR 5y	-60.77%
CAGR/Max DD 3y (Calmar Ratio)	-0.62
CAGR/Mean DD 3y (Pain Ratio)	-1.02
Sharpe Ratio 12m	-1.59
Alpha	-108.38
Beta	1.408
Volatility	122.52%
Current Volume	402.3k
Average Volume 20d	463.8k
Stop Loss	1.4 (-11.4%)
Signal	0.07

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-40.3m TTM) > 0 and > 6% of Revenue (6% = 18.7k TTM)

FCFTA -0.16 (>2.0%) and ΔFCFTA 13.84pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.16 (>3.0%) and CFO -20.6m > Net Income -40.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 0.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (11.0m) change vs 12m ago -5.03% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.28% (prev 0.0%; Δ 0.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -238.6 (EBITDA TTM -40.9m / Interest Expense TTM 172.3k) >= 6 (WARN >= 3)

Altman Z'' -13.78

(A) -0.21 = (Total Current Assets 24.6m - Total Current Liabilities 51.8m) / Total Assets 127.7m

(B) -1.81 = Retained Earnings (Balance) -230.8m / Total Assets 127.7m

warn (B) unusual magnitude: -1.81 — check mapping/units

(D) -3.84 = Book Value of Equity -230.8m / Total Liabilities 60.1m

Total Rating: -13.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.09

1. Piotroski 1.0pt = -4.0

2. FCF Yield -88.07% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda 0.13 = 2.49

6. ROIC - WACC (= -76.03)% = -12.50

7. RoE -61.66% = -2.50

8. Rev. Trend 38.87% = 2.91

9. EPS Trend -76.33% = -3.82

What is the price of CTXR shares?

As of November 03, 2025, the stock is trading at USD 1.58 with a total of 402,325 shares traded.
Over the past week, the price has changed by -2.17%, over one month by +18.80%, over three months by +13.67% and over the past year by -81.89%.

Is Citius Pharmaceuticals a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Citius Pharmaceuticals (NASDAQ:CTXR) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.09 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTXR is around 0.92 USD . This means that CTXR is currently overvalued and has a potential downside of -41.77%.

Is CTXR a buy, sell or hold?

Citius Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CTXR.

Strong Buy: 1
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CTXR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	6	279.7%
Analysts Target Price	6	279.7%
ValueRay Target Price	1.1	-32.9%

CTXR Fundamental Data Overview October 23, 2025

Market Cap USD = 28.6m (28.6m USD * 1.0 USD.USD)
P/E Forward = 3.5945
P/B = 0.3478
Beta = 1.408
Revenue TTM = 311.9k USD
EBIT TTM = -41.1m USD
EBITDA TTM = -40.9m USD
Long Term Debt = 881.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 229.4k USD (from shortTermDebt, last quarter)
Debt = 881.7k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.21m USD (from netDebt column, last quarter)
Enterprise Value = 23.4m USD (28.6m + Debt 881.7k - CCE 6.09m)
Interest Coverage Ratio = -238.6 (Ebit TTM -41.1m / Interest Expense TTM 172.3k)
FCF Yield = -88.07% (FCF TTM -20.6m / Enterprise Value 23.4m)
FCF Margin = -6601 % (FCF TTM -20.6m / Revenue TTM 311.9k)
Net Margin = -12.9k% (Net Income TTM -40.3m / Revenue TTM 311.9k)
Gross Margin = 1.19% ((Revenue TTM 311.9k - Cost of Revenue TTM 308.1k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.18 (Enterprise Value 23.4m / Total Assets 127.7m)
Interest Expense / Debt = 19.54% (Interest Expense 172.3k / Debt 881.7k)
Taxrate = -2.96% (negative due to tax credits) (264.2k / -8.94m)
NOPAT = -42.3m (EBIT -41.1m * (1 - -2.96%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 0.47 (Total Current Assets 24.6m / Total Current Liabilities 51.8m)
Debt / Equity = 0.01 (Debt 881.7k / totalStockholderEquity, last quarter 65.1m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -5.21m / EBITDA -40.9m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -5.21m / FCF TTM -20.6m)
Total Stockholder Equity = 65.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.54% (Net Income -40.3m / Total Assets 127.7m)
RoE = -61.66% (Net Income TTM -40.3m / Total Stockholder Equity 65.3m)
RoCE = -62.11% (EBIT -41.1m / Capital Employed (Equity 65.3m + L.T.Debt 881.7k))
RoIC = -64.56% (negative operating profit) (NOPAT -42.3m / Invested Capital 65.6m)
WACC = 11.47% (E(28.6m)/V(29.5m) * Re(11.20%) + D(881.7k)/V(29.5m) * Rd(19.54%) * (1-Tc(-0.03)))
Discount Rate = 11.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.92%
Fair Price DCF = unknown (Cash Flow -20.6m)
EPS Correlation: -76.33 | EPS CAGR: -21.46% | SUE: -1.29 | # QB: 0
Revenue Correlation: 38.87 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CTXR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle